How to Help Your Patients Save Money on Exparel: A Provider's Guide to Savings Programs

Exparel's high cost per vial — approximately $378–$444 at wholesale, and upward of $444 at retail — creates real access barriers for patients and financial strain for facilities that don't have adequate reimbursement mechanisms in place. As the prescribing or administering provider, you have several tools available to help your patients access Exparel without bearing the full cost, and to ensure your facility is capturing appropriate reimbursement.

This guide covers everything providers need to know about Exparel's savings ecosystem in 2026: the NOPAIN Act's reimbursement impact, PaciraConnect support services, commercial insurance navigation, Medicare billing, and financial assistance options for uninsured or underinsured patients.

Understanding How Exparel Is Billed

Unlike outpatient oral prescriptions, Exparel is billed through the medical benefit — not the pharmacy benefit. This has several important implications:

• Retail pharmacy discount cards (GoodRx, SingleCare, RxSaver) do not apply.
• The patient's pharmacy deductible and prescription drug out-of-pocket maximum do not apply.
• Billing flows through the facility (hospital or ASC) charge, with the drug cost embedded in or added to the procedure charge.
• Coverage and patient cost share depend on the patient's medical insurance plan, in-network status, and whether they've met their medical deductible and out-of-pocket maximum.

The NOPAIN Act: A Game-Changer for Medicare Outpatient Cases

Effective January 1, 2025, the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act authorized the Centers for Medicare & Medicaid Services (CMS) to make a separate add-on payment for FDA-approved non-opioid analgesics like Exparel when administered in the Medicare outpatient setting — specifically in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs).

Before the NOPAIN Act, Exparel used in the outpatient setting was typically packaged into the facility's procedure payment (APC for HOPDs or composite rate for ASCs), meaning no additional payment was made for using Exparel versus a $3 vial of standard bupivacaine. This made it financially irrational for many facilities to use Exparel.

The NOPAIN Act directly addresses this by providing a separate pass-through or add-on payment for qualifying non-opioid drugs. For facilities with Medicare outpatient surgical volume, this is a direct reimbursement improvement that makes Exparel economically viable for many more procedures.

Action step for facilities: Ensure your coding and billing team is capturing the appropriate HCPCS/CPT codes for Exparel under the NOPAIN Act provisions. If Exparel was previously removed from formulary due to reimbursement concerns for Medicare patients, revisit that formulary decision with your P&T committee.

PaciraConnect: The Manufacturer's Reimbursement Hub

Pacira BioSciences operates PaciraConnect, a dedicated support hub for providers and facilities navigating Exparel reimbursement. PaciraConnect offers:

• Prior authorization (PA) support: Assistance with completing and submitting PA requests to commercial insurers, including clinical summaries and peer-reviewed literature supporting the use of Exparel for specific procedure types.
• Appeals support: When PA requests are denied, PaciraConnect can help draft appeals using clinical rationale and outcomes data specific to the insurer's coverage criteria.
• Billing code guidance: HCPCS billing codes, modifier requirements, and documentation requirements for proper Exparel billing.
• NOPAIN Act guidance: Help understanding and implementing NOPAIN Act add-on payment capture for Medicare outpatient cases.

Reach PaciraConnect at 1-855-RX-EXPAREL (1-855-793-9727). This should be one of the first calls your billing or surgical coordinator team makes when encountering coverage issues with Exparel.

Navigating Commercial Insurance Coverage

Commercial insurance coverage for Exparel varies significantly by insurer and procedure type. Large national payers (Aetna, UnitedHealthcare, Cigna, BCBS plans) have generally expanded coverage to include Exparel for procedures like total joint arthroplasty, thoracic surgery, and shoulder nerve blocks, though prior authorization requirements are common.

Best practices for PA success:

• Submit the PA request well before the procedure date (at least 5–7 business days).
• Include the specific CPT procedure code and HCPCS code for Exparel (J0670 for bupivacaine, if applicable under the insurer's system).
• Document clinical rationale: high-risk opioid patient, prior adverse reaction to opioids, opioid use disorder history, or procedure type with documented Exparel benefit in literature.
• Attach peer-reviewed clinical evidence for your specific procedure type, especially for non-joint-replacement surgeries where payers may apply stricter criteria.

Patient Assistance for Uninsured or Underinsured Patients

For patients who are uninsured or underinsured, Pacira BioSciences may offer financial assistance through patient assistance programs (PAPs). Eligibility typically requires:

• No insurance coverage for Exparel (uninsured or benefit denial)
• Income below program thresholds
• U.S. residency and valid prescription/surgical order

Direct your team to contact PaciraConnect to discuss PAP eligibility for specific patients: 1-855-RX-EXPAREL.

Institutional Pharmacoeconomics: Making the Case for Formulary Inclusion

If Exparel is not on your facility's formulary, advocating for inclusion requires a pharmacoeconomic argument. Key data points that support the case:

• Length-of-stay reductions: Studies have shown Exparel use in colorectal surgery was associated with a $1,435 reduction in total cost of care per patient — primarily from reduced hospital stay.
• Opioid use reduction: Studies show patients who received Exparel consumed an average of 12.2 mg of opioids postoperatively vs. 19 mg for standard bupivacaine HCl — a 36% reduction.
• NOPAIN Act revenue: For Medicare outpatient volume, the add-on payment improves the cost-benefit ratio significantly.
• ERAS alignment: Exparel fits naturally into ERAS protocols, which are associated with improved outcomes and shorter stays across multiple procedure categories.

Helping Patients Access Post-Surgical Prescriptions

Even when Exparel is successfully used in surgery, patients are discharged with oral prescriptions for continued pain management. medfinder for providers is a paid service that calls local pharmacies on behalf of your patients to locate which ones have their medications in stock, then texts results directly to the patient. This can reduce discharge friction and prevent patients from returning to the ER because they couldn't find a pharmacy with their prescription.

See also: How to Help Your Patients Find Exparel in Stock: A Provider's Guide.

And: Exparel Access Issues: What Providers and Prescribers Need to Know in 2026.